Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate

Human Psychopharmacology
Paolo GirardiRoberto Brugnoli

Abstract

Long-acting injectable (LAI) antipsychotics can improve medication adherence and reduce hospitalisation rates compared with oral treatments. Paliperidone palmitate (PAL) and aripiprazole monohydrate (ARI) LAI treatments were associated with improvements in global functioning in patients with schizophrenia. The objective of this study was to assess the predictive factors of better overall functioning in patients with chronic schizophrenia and schizoaffective disorder treated with PAL and ARI. Enrolled were 143 (97 males, 46 females, mean age 38.24 years, SD = 12.65) patients with a diagnosis of schizophrenia or schizoaffective disorder, whom we allocated in two groups (PAL and ARI treatments). We assessed global functioning, amount of oral medications, adherence to oral treatment, and number of hospitalisations before LAI introduction and at assessment time point. Longer treatment time with LAIs (p < .001), lower number of oral drugs (p < .001), and hospitalisations (p = .002) before LAI introduction, and shorter duration of illness (p = .038) predicted better Global Assessment of Functioning scores in the whole sample (R2  = 0.337). Early administration and longer duration of ARI or PAL treatments could play a significant role ...Continue Reading

References

Dec 9, 2003·The Journal of Clinical Psychiatry·Samuel J Keith, John M Kane
Jun 29, 2007·Schizophrenia Research·C Daniel MullinsAntony D Loebel
Jan 18, 2008·PharmacoEconomics·A George Awad, Lakshmi N P Voruganti
Apr 9, 2009·Progress in Neuro-psychopharmacology & Biological Psychiatry·Jihyung HongJacqueline Brown
Dec 3, 2010·Psychiatric Services : a Journal of the American Psychiatric Association·Kathleen LangJoseph Menzin
Jul 16, 2011·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Emmanuel StipMarc-André Roy
Sep 29, 2011·The Journal of Clinical Psychiatry·John M Kane
Sep 12, 2012·Schizophrenia Bulletin·Abraham M Nussbaum, T Scott Stroup
Dec 12, 2012·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanUNKNOWN WFSBP Task force on Treatment Guidelines for Schizophrenia
Aug 9, 2013·JAMA Psychiatry·René S Kahn, Richard S E Keefe
Aug 16, 2013·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Rahul ManchandaNicola Banks
Jun 27, 2015·The Journal of Clinical Psychiatry·Herbert Y MeltzerElliot W Ehrich
Sep 26, 2015·Early Intervention in Psychiatry·Georgia L StevensJacqueline Zummo
Dec 30, 2015·Current Medical Research and Opinion·Pierre Chue, James Chue
Jan 23, 2016·Neuropsychiatric Disease and Treatment·Craig KarsonSteve J Offord
Mar 5, 2016·Expert Opinion on Pharmacotherapy·Larry AlphsIbrahim Turkoz
Jan 24, 2017·Journal of Child and Adolescent Psychopharmacology·Sarah LytleMartha Sajatovic

❮ Previous
Next ❯

Citations

Jan 26, 2021·International Clinical Psychopharmacology·Nora Palomar-CiriaEnrique Baca-García
Mar 30, 2021·Expert Opinion on Drug Safety·Renato de FilippisMaria Rosaria Anna Muscatello

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Psychiatric Services : a Journal of the American Psychiatric Association
Kathleen LangJoseph Menzin
Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists
Robert A LasserJohn M Kane
© 2022 Meta ULC. All rights reserved